Work

Rhabdoid tumors as a novel target for PSMA-directed CAR T cell therapy

Year: 2026

Type: article

Abstract: efficacy was also assessed in xenograft mouse models of non-CNS tumors, where PSMA CAR T cell treatment resulted in significant tumor regression and robust accumulation of CAR T cells within the tumor microenvironment. Together, these findings establish PSMA as a promising surface antigen beyond prostate cancer and provide preclinical evidence supporting the development of PSMA-directed therapies for this highly lethal pediatric cancer.

Source: Molecular Therapy Oncology

DOI: 10.1016/j.omton.2026.201125